These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34893157)

  • 21. Endoplasmic Reticulum and Lysosomal Quality Control of Four Nonsense Mutants of Iduronate 2-Sulfatase Linked to Hunter's Syndrome.
    Marazza A; Galli C; Fasana E; Sgrignani J; Burda P; Fassi EMA; Baumgartner M; Cavalli A; Molinari M
    DNA Cell Biol; 2020 Feb; 39(2):226-234. PubMed ID: 31895584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic analysis of 63 Chinese patients with mucopolysaccharidosis type II: Functional characterization of seven novel IDS variants.
    Zhang W; Xie T; Sheng H; Shao Y; Lin Y; Jiang M; Xu A; Su X; Liu Z; Zhao X; Liu L; Huang Y
    Clin Chim Acta; 2019 Apr; 491():114-120. PubMed ID: 30639582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic analysis of 17 children with Hunter syndrome: identification and functional characterization of four novel mutations in the iduronate-2-sulfatase gene.
    Chistiakov DA; Kuzenkova LM; Savost'anov KV; Gevorkyan AK; Pushkov AA; Nikitin AG; Vashakmadze ND; Zhurkova NV; Podkletnova TV; Namazova-Baranova LS; Baranov AA
    J Genet Genomics; 2014 Apr; 41(4):197-203. PubMed ID: 24780617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis.
    Sukegawa-Hayasaka K; Kato Z; Nakamura H; Tomatsu S; Fukao T; Kuwata K; Orii T; Kondo N
    J Inherit Metab Dis; 2006 Dec; 29(6):755-61. PubMed ID: 17091340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
    Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular analysis in two siblings African patients with severe form of Hunter Syndrome: identification of a novel (p.Y54X) nonsense mutation.
    Mutesa L; Muganga N; Lissens W; Boemer F; Schoos R; Pierquin G; Bours V
    J Trop Pediatr; 2007 Dec; 53(6):434-7. PubMed ID: 17616540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment.
    Mohamed S; He QQ; Singh AA; Ferro V
    Adv Carbohydr Chem Biochem; 2020; 77():71-117. PubMed ID: 33004112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities for Mucopolysaccharidosis Type II.
    Matsuhisa K; Imaizumi K
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into Hunter syndrome from the structure of iduronate-2-sulfatase.
    Demydchuk M; Hill CH; Zhou A; Bunkóczi G; Stein PE; Marchesan D; Deane JE; Read RJ
    Nat Commun; 2017 Jun; 8():15786. PubMed ID: 28593992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotype-phenotype correlation in 44 Czech, Slovak, Croatian and Serbian patients with mucopolysaccharidosis type II.
    Dvorakova L; Vlaskova H; Sarajlija A; Ramadza DP; Poupetova H; Hruba E; Hlavata A; Bzduch V; Peskova K; Storkanova G; Kecman B; Djordjevic M; Baric I; Fumic K; Barisic I; Reboun M; Kulhanek J; Zeman J; Magner M
    Clin Genet; 2017 May; 91(5):787-796. PubMed ID: 27883178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of four novel mutations in the iduronate-2-sulfatase gene. Mutations in brief no. 123. Online.
    Balzano N; Villani GR; Grosso M; Izzo P; Di Natale P
    Hum Mutat; 1998; 11(4):333. PubMed ID: 10215411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calnexin promotes the folding of mutant iduronate 2-sulfatase related to mucopolysaccharidosis type II.
    Osaki Y; Matsuhisa K; Che W; Kaneko M; Asada R; Masaki T; Imaizumi K; Saito A
    Biochem Biophys Res Commun; 2019 Jun; 514(1):217-223. PubMed ID: 31029429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II.
    Sonoda H; Morimoto H; Yoden E; Koshimura Y; Kinoshita M; Golovina G; Takagi H; Yamamoto R; Minami K; Mizoguchi A; Tachibana K; Hirato T; Takahashi K
    Mol Ther; 2018 May; 26(5):1366-1374. PubMed ID: 29606503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome).
    Garcia AR; Pan J; Lamsa JC; Muenzer J
    J Inherit Metab Dis; 2007 Nov; 30(6):924-34. PubMed ID: 17876721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of
    Smith MC; Belur LR; Karlen AD; Erlanson O; Podetz-Pedersen KM; McKenzie J; Detellis J; Gagnidze K; Parsons G; Robinson N; Labarre S; Shah S; Furcich J; Lund TC; Tsai HC; McIvor RS; Bonner M
    Hum Gene Ther; 2022 Dec; 33(23-24):1279-1292. PubMed ID: 36226412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome.
    Chiong MA; Canson DM; Abacan MA; Baluyot MM; Cordero CP; Silao CL
    Orphanet J Rare Dis; 2017 Jan; 12(1):7. PubMed ID: 28077157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and characterization of 20 novel pathogenic variants in 60 unrelated Indian patients with mucopolysaccharidoses type I and type II.
    Uttarilli A; Ranganath P; Matta D; Md Nurul Jain J; Prasad K; Babu AS; Girisha KM; Verma IC; Phadke SR; Mandal K; Puri RD; Aggarwal S; Danda S; Sankar VH; Kapoor S; Bhat M; Gowrishankar K; Hasan AQ; Nair M; Nampoothiri S; Dalal A
    Clin Genet; 2016 Dec; 90(6):496-508. PubMed ID: 27146977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.
    Laoharawee K; DeKelver RC; Podetz-Pedersen KM; Rohde M; Sproul S; Nguyen HO; Nguyen T; St Martin SJ; Ou L; Tom S; Radeke R; Meyer KE; Holmes MC; Whitley CB; Wechsler T; McIvor RS
    Mol Ther; 2018 Apr; 26(4):1127-1136. PubMed ID: 29580682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II.
    Garcia AR; DaCosta JM; Pan J; Muenzer J; Lamsa JC
    Mol Genet Metab; 2007 Jun; 91(2):183-90. PubMed ID: 17459751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.